Ascendis Pharma A/S vs General Dynamics Corporation — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while General Dynamics Corporation trades at $391.11 (market cap $106.03B). The key difference: General Dynamics Corporation is far larger — about 6.4× Ascendis Pharma A/S's market cap, and General Dynamics Corporation pays a 1.62% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GD | |
|---|---|---|
Market Cap | $16.67B | $106.03B |
Sector | Health | Industrials |
52-Week High | $277.18 | $395.97 |
52-Week Low | $189.74 | $312.53 |
Enterprise Value | $17.04B | $111.17B |
Dividend Yield | — | 1.62% |
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →